#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	4398	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2300	451.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1401	1401	C	490	C,T,G	453,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	4398	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2300	451.5	0	HET	.	.	.	C207T	.	207	207	C	424	424	C	404	C,T	275,84	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7216	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4105	435.9	0	.	n	.	0	T695C	SNP	695	695	T	1319	1319	C	527	C,A	488,4	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7216	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4105	435.9	0	.	n	.	0	A1638G	SNP	1638	1638	A	2262	2262	G	522	G,A	494,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7216	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4105	435.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2595	2595	C	498	C,T,G	471,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7216	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4105	435.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3221	3221	T	544	T,C,G	514,3,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7216	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4105	435.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2669	2669	A	482	A	462	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	582	folP	855	855	100.0	folP.l15.c4.ctg.1	2024	71.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1209	1211	AGC	84;86;87	A;G;C,A	80;83;80,1	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1186	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4044	72.1	1	SNP	p	S91F	1	.	.	271	273	TTC	1007	1009	TTC	67;68;68	T;T;C	61;60;64	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1186	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4044	72.1	1	SNP	p	G95N	0	.	.	283	285	GGC	1019	1021	GGC	68;68;68	G;G;C	66;66;63	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1186	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4044	72.1	1	SNP	p	D95G	1	.	.	283	285	GGC	1019	1021	GGC	68;68;68	G;G;C	66;66;63	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	470	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1733	67.1	1	SNP	p	G45D	0	.	.	133	135	GGC	669	671	GGC	106;109;109	G;G;C	96;100;103	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	264	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1582	41.2	0	.	n	.	0	A197.	DEL	197	197	A	857	857	A	79	A,C	74,1	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1304	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3456	92.4	1	SNP	p	D86N	0	.	.	256	258	GAC	887	889	GAC	88;88;94	G;A;C	70;59;76	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1304	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3456	92.4	1	SNP	p	R87W	0	.	.	259	261	CGT	890	892	CGT	94;95;98	C;G;T	84;75;86	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1304	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3456	92.4	1	SNP	p	S87R	1	.	.	259	261	CGT	890	892	CGT	94;95;98	C;G;T	84;75;86	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1304	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3456	92.4	1	SNP	p	R87I	0	.	.	259	261	CGT	890	892	CGT	94;95;98	C;G;T	84;75;86	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1304	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3456	92.4	1	SNP	p	S88P	0	.	.	262	264	TCC	893	895	TCC	99;98;98	T,G,C;C,T;C	81,1,1;85,2;87	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1140	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3140	88.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1809	1811	GGC	98;99;99	G;G,A;C	84;84,1;85	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	A311V	0	.	.	931	933	GCC	1429	1431	GCC	113;114;114	G;C;C,G	108;108;106,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	I312M	1	.	.	934	936	ATG	1432	1434	ATG	114;117;118	A;T;G	108;111;110	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	V316T	1	.	.	946	948	ACC	1444	1446	ACC	118;118;115	A;C;C	108;111;108	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	T316P	0	.	.	946	948	ACC	1444	1446	ACC	118;118;115	A;C;C	108;111;108	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1945	1947	ACC	115;115;115	A;C,A;C	104;103,2;108	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1999	2001	GCG	110;109;109	G;C,G;G	101;92,1;101	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1999	2001	GCG	110;109;109	G;C,G;G	101;92,1;101	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2122	2124	GGT	90;90;87	G;G,T;T,G	88;86,2;84,1	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2131	2133	AGC	81;80;79	A,G;G,A;C,G	66,1;69,1;71,1	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	946	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2489	91.8	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2149	2151	CCG	60;59;59	C;C;G,T	48;46;52,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1386	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3427	98.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1779	1781	CCG	151;150;150	C,G,T;C;G,C,T	127,2,1;138;110,7,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	620	porA	1146	1146	99.91	porA.l6.c17.ctg.1	2565	59.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	1109	1109	C	63	C	58	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	269	90.48	porB1a.l6.c4.ctg.1	1595	15.2	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1351	1353	AAT	15;15;15	A;A;T	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	269	90.48	porB1a.l6.c4.ctg.1	1595	15.2	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1354	1356	AAT	15;15;13	A;A;T	13;13;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	269	90.48	porB1a.l6.c4.ctg.1	1595	15.2	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1378	1380	GCA	8;8;8	G;C;A	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	269	90.48	porB1a.l6.c4.ctg.1	1595	15.2	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1401	1403	GTA	8;8;8	G;T;A	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	98	porB1a	984	269	90.48	porB1a.l6.c4.ctg.1	1595	15.2	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1410	1410	A	8	A	6	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	710	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	2358	75.0	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	769	771	CAG	92;90;89	C;A;G,C	89;87;85,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	710	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	2358	75.0	1	SNP	p	G120K	1	.	.	358	360	AAG	1009	1011	AAG	113;112;113	A;A;G,C	103;104;102,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	710	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	2358	75.0	1	SNP	p	N121D	0	.	.	361	363	AAC	1012	1014	AAC	114;114;114	A;A;C,T	103;102;104,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	710	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	2358	75.0	1	SNP	p	A121N	1	.	.	361	363	AAC	1012	1014	AAC	114;114;114	A;A;C,T	103;102;104,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2576	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5217	122.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	328	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1589	51.5	1	SNP	p	V57M	1	.	.	169	171	ATG	796	798	ATG	105;105;105	A;T;G	100;104;104	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
